Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 87

    1.

    Can abuse deterrent formulations make a difference? Expectation and speculation.

    Budman SH, Grimes Serrano JM, Butler SF.

    Harm Reduct J. 2009 May 29;6:8.

    PMID:
    19480676
    [PubMed]
    Free PMC Article
    2.

    Abuse-deterrent opioid formulations: are they a pipe dream?

    Katz N.

    Curr Rheumatol Rep. 2008 Jan;10(1):11-8. Review.

    PMID:
    18457606
    [PubMed - indexed for MEDLINE]
    3.

    Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation.

    Butler SF, Black R, Grimes Serrano JM, Folensbee L, Chang A, Katz N.

    Pain Med. 2010 Jan;11(1):81-91. Epub 2009 Nov 25.

    PMID:
    20002324
    [PubMed - indexed for MEDLINE]
    4.

    Abuse risks and routes of administration of different prescription opioid compounds and formulations.

    Butler SF, Black RA, Cassidy TA, Dailey TM, Budman SH.

    Harm Reduct J. 2011 Oct 19;8:29.

    PMID:
    22011626
    [PubMed]
    Free PMC Article
    5.

    Update on abuse-resistant and abuse-deterrent approaches to opioid formulations.

    Webster L.

    Pain Med. 2009 Jul;10 Suppl 2:S124-33. Review.

    PMID:
    19691683
    [PubMed - indexed for MEDLINE]
    6.

    College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement.

    Zacny J, Bigelow G, Compton P, Foley K, Iguchi M, Sannerud C.

    Drug Alcohol Depend. 2003 Apr 1;69(3):215-32. Review.

    PMID:
    12633908
    [PubMed - indexed for MEDLINE]
    7.

    Prescription opioid abuse and diversion in an urban community: the results of an ultrarapid assessment.

    Inciardi JA, Surratt HL, Cicero TJ, Beard RA.

    Pain Med. 2009 Apr;10(3):537-48.

    PMID:
    19416440
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    8.

    Prescription opioid abuse, pain and addiction: clinical issues and implications.

    Ling W, Mooney L, Hillhouse M.

    Drug Alcohol Rev. 2011 May;30(3):300-5. doi: 10.1111/j.1465-3362.2010.00271.x. Review.

    PMID:
    21545561
    [PubMed - in process]
    9.

    Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers.

    Butler SF, Benoit C, Budman SH, Fernandez KC, McCormick C, Venuti SW, Katz N.

    Harm Reduct J. 2006 Feb 2;3:5.

    PMID:
    16457713
    [PubMed]
    Free PMC Article
    10.

    Challenges in the development of prescription opioid abuse-deterrent formulations.

    Katz NP, Adams EH, Chilcoat H, Colucci RD, Comer SD, Goliber P, Grudzinskas C, Jasinski D, Lande SD, Passik SD, Schnoll SH, Sellers E, Travers D, Weiss R.

    Clin J Pain. 2007 Oct;23(8):648-60. Review.

    PMID:
    17885342
    [PubMed - indexed for MEDLINE]
    11.

    Measuring attractiveness for abuse of prescription opioids.

    Butler SF, Fernandez KC, Chang A, Benoit C, Morey LC, Black R, Katz N.

    Pain Med. 2010 Jan;11(1):67-80. Epub 2009 Nov 25.

    PMID:
    20002325
    [PubMed - indexed for MEDLINE]
    12.

    Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation.

    Passik SD, Hays L, Eisner N, Kirsh KL.

    J Pain Palliat Care Pharmacother. 2006;20(2):5-13.

    PMID:
    16702131
    [PubMed - indexed for MEDLINE]
    13.

    Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

    Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

    Pain Pract. 2008 Jul-Aug;8(4):287-313. Epub 2008 May 23.

    PMID:
    18503626
    [PubMed - indexed for MEDLINE]
    14.

    Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction.

    White AG, Birnbaum HG, Rothman DB, Katz N.

    Appl Health Econ Health Policy. 2009;7(1):61-70. doi: 10.2165/00148365-200907010-00006.

    PMID:
    19558195
    [PubMed - indexed for MEDLINE]
    16.

    Development of opioid formulations with limited diversion and abuse potential.

    Fudala PJ, Johnson RE.

    Drug Alcohol Depend. 2006 Jun;83 Suppl 1:S40-7. Epub 2006 Mar 24.

    PMID:
    16564141
    [PubMed - indexed for MEDLINE]
    17.

    Prescription opioid abuse among drug-involved street-based sex workers.

    Surratt HL, Inciardi JA, Kurtz SP.

    J Opioid Manag. 2006 Sep-Oct;2(5):283-9.

    PMID:
    17319260
    [PubMed - indexed for MEDLINE]
    18.

    National drug control policy and prescription drug abuse: facts and fallacies.

    Manchikanti L.

    Pain Physician. 2007 May;10(3):399-424. Review.

    PMID:
    17525776
    [PubMed - indexed for MEDLINE]
    Free Article
    19.

    Formulation considerations for the development of medications with abuse potential.

    Mansbach RS, Moore RA Jr.

    Drug Alcohol Depend. 2006 Jun;83 Suppl 1:S15-22. Epub 2006 Feb 10.

    PMID:
    16472940
    [PubMed - indexed for MEDLINE]
    20.

    Economic burden of prescription opioid misuse and abuse.

    Strassels SA.

    J Manag Care Pharm. 2009 Sep;15(7):556-62. Review.

    PMID:
    19739878
    [PubMed - indexed for MEDLINE]
    Free Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk